Insulin Pump Tandem denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for insulin pump tandem are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Deny a Tandem Insulin Pump as "Not FDA-Approved"

This denial is almost always a misclassification. Tandem Diabetes Care insulin pumps — including the t:slim X2 — hold FDA clearance as Class II medical devices. Insurers occasionally issue this denial language in error when the specific software version, algorithm feature, or accessory being requested carries a separate FDA clearance status than the base pump, or when the claim coding does not match the cleared device configuration on file.

## Why This Denial Is Appealable

If the exact device and configuration your prescriber ordered is FDA-cleared, the "not FDA-approved" rationale has no factual basis and the denial must be reversed on that ground alone. Federal law requires Cigna to base denials on accurate clinical and regulatory information. An appeal backed by the device's FDA 510(k) clearance documentation is typically strong.

## Federal Appeal Framework

• Internal appeal: You have the right to a full internal appeal under ACA §2719 and ERISA §503. Submit within the timeframe shown on your Explanation of Benefits (EOB) — typically 180 days.
• External review: If the internal appeal fails, you may request an Independent Review Organization (IRO) review. Federal rules under ACA §2719 give you approximately four months from the final internal denial to file. An external reviewer is not bound by Cigna's own criteria and reviews the clinical and regulatory record de novo.
• Expedited review: If delaying the device would seriously jeopardize your health (e.g., severe hypoglycemia unawareness, inability to manage diabetes safely), request an expedited appeal — decisions are typically required within 72 hours.

## Documentation to Gather

1. FDA clearance documentation: Download the 510(k) summary for the specific Tandem device and software version from the FDA device database (accessdata.fda.gov). Attach this directly to your appeal. 2. Prescriber letter: A letter from your endocrinologist or treating physician confirming the exact device model ordered matches the FDA-cleared product. 3. Diagnosis and clinical history: Chart notes confirming your diabetes diagnosis, current treatment history, and why this specific pump is medically necessary. 4. Denial letter: Include Cigna's denial letter and highlight the regulatory basis they cited so the reviewer can address it point by point.

## Criteria-Mapping Structure

Copy each stated denial rationale from Cigna's letter. For each item, provide the direct documentary rebuttal — most importantly the FDA 510(k) clearance number and the device's cleared indications for use. If the denial references a specific policy number or clinical coverage criteria, obtain Cigna's current published Medical Coverage Policy for insulin pumps and show that the ordered device satisfies each listed requirement using exact chart facts and device documentation.